Klinische Prüfungen

Dacogen2004

- Indikation: AML Rezidiv oder refraktär
- Prüfpräparat: Cytarabin
- Status: offen für Rekrutierung

"Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia"

AZA-AML-004

- Indikation: AML molekulares Rezidiv nach erster CR
- Prüfpräparat: Azacitidine vs keine Behandlung
- Status: in Vorbereitung

A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 2 STUDY, WITH A SAFETY RUN-IN PART TO EVALUATE SAFETY, PHARMACODYNAMICS AND EFFICACY OF AZACITIDINE COMPARED TO NO ANTICANCER TREATMENT IN CHILDREN AND YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA IN MOLECULAR RELAPSE AFTER FIRST COMPLETE REMISSION

AZA-JMML-001

- Indikation: de novo MDS oder JMML vor SZT
- Prüfpräparat: Azacitidine
- Status: in Vorbereitung

A PHASE 2, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND ACTIVITY OF AZACITIDINE AND TO COMPARE AZACITIDINE TO HISTORICAL CONTROLS IN PEDIATRIC SUBJECTS WITH NEWLY DIAGNOSED ADVANCED MYELODYSPLASTIC SYNDROME OR JUVENILE MYELOMONOCYTIC LEUKEMIA BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION

997HA306 "Biogen – PUP Studie"

- Indikation: Hämophilie A
- Prüfpräparat: Faktor VIII
- Status: in Vorbereitung

Prüfplantitel "An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A" (997HA306)